EUAA
The first and only test
to deliver genomic and epigenomic insights
in one.1*
CHIP, clonal hematopoiesis of indeterminate potential; MSI, microsatellite instability; TMB, tumor mutation burden.
*Guardant360 Liquid is guideline-complete for genomic biomarkers.
†Includes TERT promoter region.
Important note: Guardant360 Liquid was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.
Product availability may vary depending on region.
Home Oncology Portfolio Partnerships European Policy